Celldex Therapeutics, Inc. CLDX
Regular-session close
After hours · Nov 20, 5:33 PM ET
- YTD
- +0.96%
- 1 year
- +9.37%
5D -0.29 (-1.03%)
- Market cap
- 2.15B
- Revenue (ttm)
- 158.00K
- EPS (ttm)
- -4.29
- Shares out
- 78.55M
- Forward P/E
- -6.57
- YTD return
- +0.96%
- 1-year return
- +9.37%
- 50-day average
- 31.11
- 200-day average
- 32.91
- Enterprise value
- 1.56B
- Volume
- 1.72M
- Avg volume
- 1.32M
- Open
- 27.05
- Previous close
- 27.96
- Day's range
- 26.64 – 28.43
- 52-week range
- 22.58 – 44.87
- Beta
- 1.03
- Analysts
- Strong Buy
- Price target
- 63.79 (+132.6%)
- Earnings date
- Feb 24, 2027
Key statistics
- Price / sales
- 13631.05
- Price / book
- 3.32
- Free cash flow
- -154.39M
- Total cash
- 650.32M
- Total debt
- 9.87M
- Return on equity
- -49.54%
- Short % of float
- 15.01%
Fundamental scorecard
4 of 25 checks passed on CLDX’s reported financials
4of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 29.00
- Target (mean)
- 63.79
- Target (high)
- 100.00
- Strong buy2
- Buy12
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate -1.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 30, 2026 | -1.05 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -1.02 | -0.96 | +0.06 | +5.88% |
| Aug 6, 2026 | Jun 30, 2026 | -1.06 | -0.94 | +0.12 | +11.32% |
| May 7, 2026 | Mar 31, 2026 | -1.15 | -1.18 | -0.03 | -2.86% |
| Feb 25, 2026 | Dec 31, 2025 | -1.00 | -1.22 | -0.22 | -22.00% |
| Nov 10, 2025 | Sep 30, 2025 | -0.88 | -1.01 | -0.13 | -14.77% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 20, 2026 | Barclays | main | Overweight | Overweight |
| Nov 20, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 9, 2026 | Canaccord Genuity | main | Buy | Buy |
| Nov 9, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Oct 2, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 23, 2026 | Leerink Partners | main | Outperform | Outperform |
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- celldex.com
News
Barclays Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $50
Celldex Drops Atopic Dermatitis Study Following Weak Phase 2 Pruritus Data HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Lowers Price Target to $58
12 Health Care Stocks Moving In Thursday's After-Market Session Celldex Reports Topline Results From Phase 2 Study Of Barzolvolimab In Atopic Dermatitis; Study Did Not Meet Key Efficacy Measures Or Internal Hurdle Rate For Continued Development
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Atopic Dermatitis Canaccord Genuity Maintains Buy on Celldex Therapeutics, Raises Price Target to $68
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $61
Celldex Therapeutics Q3 EPS $(0.96) Beats $(1.02) Estimate
Your note
Sign in to keep a note on CLDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| JIMENEZ FREDDY A | General Counsel | Sale | Dec 3, 2025 | 30,796 |
| MARTIN SAMUEL BATES | Chief Financial Officer | Conversion of Exercise of derivative security | Jan 1, 2026 | 32,942 |
| PEPIN RONALD A | Officer | Conversion of Exercise of derivative security | Dec 14, 2025 | 20,097 |
| WRIGHT RICHARD M | Former | Conversion of Exercise of derivative security | Nov 12, 2025 | 20,833 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wellington Management Group, LLP | 13.58% | 10,671,399 | 292.61M | Sep 29, 2026 |
| FMR, LLC | 10.99% | 8,637,498 | 236.84M | Sep 29, 2026 |
| Blackrock Inc. | 8.84% | 6,948,371 | 190.52M | Sep 29, 2026 |
| Kynam Capital Management, LP | 6.45% | 5,066,051 | 138.91M | Sep 29, 2026 |
| Price (T.Rowe) Associates Inc | 5.58% | 4,385,929 | 120.26M | Sep 29, 2026 |
| State Street Corporation | 4.43% | 3,478,549 | 95.38M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 4.82% | 3,783,994 | 103.76M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 2,487,758 | 68.21M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.57% | 2,020,869 | 55.41M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.04% | 1,603,138 | 43.96M | Sep 29, 2026 |
| Vanguard Explorer Fund | 1.84% | 1,447,608 | 39.69M | Jul 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1.60% | 1,254,603 | 34.40M | Jun 29, 2026 |
